

Karthik V Giridhar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9403078/publications.pdf>

Version: 2024-02-01

25
papers

636
citations

758635

12
h-index

752256

20
g-index

26
all docs

26
docs citations

26
times ranked

993
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent and Selective Disruption of Protein Kinase D Functionality by a Benzoxoloazepinolone. <i>Journal of Biological Chemistry</i> , 2008, 283, 33516-33526.	1.6	124
2	Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. <i>Cancer</i> , 2020, 126, 26-36.	2.0	82
3	Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. <i>BMC Chemical Biology</i> , 2010, 10, 5.	1.6	75
4	A contemporary review of male breast cancer: current evidence and unanswered questions. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 599-614.	2.7	63
5	Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. <i>Oncotarget</i> , 2017, 8, 63703-63714.	0.8	55
6	Hereditary Cancer Syndromesâ€”A Primer on Diagnosis and Management. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1084-1098.	1.4	39
7	Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1564-1582.	1.4	35
8	Hereditary Cancer Syndromesâ€”A Primer on Diagnosis and Management, Part 2: Gastrointestinal Cancer Syndromes. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1099-1116.	1.4	33
9	A protein kinase C/protein kinase D pathway protects LNCaP prostate cancer cells from phorbol ester-induced apoptosis by promoting ERK1/2 and NF- κ B activities. <i>Carcinogenesis</i> , 2011, 32, 1198-1206.	1.3	29
10	Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 1973-1976.	0.6	28
11	Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 431-437.	2.0	20
12	Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2326.	1.8	16
13	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 131.	2.3	13
14	Available and emerging molecular markers in the clinical management of breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 919-928.	1.5	9
15	Hepatitis, Pancreatitis and Rash in a Patient With Chronic Lymphocytic Leukemia. <i>Gastroenterology</i> , 2019, 157, e8-e9.	0.6	4
16	Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences?. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 923-926.	1.0	3
17	High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy. <i>Clinical Nephrology</i> , 2018, 89, 291-299.	0.4	3
18	A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer. <i>Breast Cancer Management</i> , 2021, 10, BMT59.	0.2	2

#	ARTICLE	IF	CITATIONS
19	Use of Multigene Prognostic Indices to Guide Clinical Decision-Making Regarding Adjuvant Systemic Therapy. <i>Current Breast Cancer Reports</i> , 2018, 10, 251-261.	0.5	1
20	Reply to On the proportion of male breast cancer among all breast cancers. <i>Cancer</i> , 2020, 126, 2034-2035.	2.0	1
21	Surveillance mammography after treatment for male breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 693-698.	1.1	1
22	Split Decision. <i>Journal of General Internal Medicine</i> , 2014, 29, 1707-1710.	1.3	0
23	Supplements to Help Prevent Neuropathy During Chemotherapy? A Cautionary Tale. <i>Journal of the National Cancer Institute</i> , 2018, 110, 551-552.	3.0	0
24	Common Considerations in Male Breast Cancer Survivors. , 2021, , 319-328.		0
25	Is microRNA expression profile in prostate cancer dependent on clinicopathologic stage or cell subtype?. <i>Translational Cancer Research</i> , 2016, 5, S1139-S1141.	0.4	0